AHIP Submits Statement For House Hearing On Medicare Prescription Drug Issues
posted by AHIP
on April 30, 2019
On April 30, 2019, AHIP submitted a statement to the House Energy and Commerce Subcommittee on Health for a hearing on prescription drug pricing in the Medicare program.
We explain that Medicare prescription drug coverage (Part D) is an example of a successful public-private partnership that provides Americans with competitive choices that both meet their needs and improve health care affordability. More than 45 million Americans choose a Part D plan for their prescription drug coverage—either through a stand-alone Part D plan, or through an integrated Medicare Advantage-Prescription Drug plan.
Our statement focuses on the following topics:
- Our serious concerns with a proposed rule, released by the Department of Health and Human Services (HHS), that would increase costs for America’s seniors and taxpayers by dramatically changing how discounts are negotiated with drug manufacturers;
- Our support for alternative solutions that will sustainably lower drug prices for all Americans;
- Our support for recent improvements to the Medicare Part D prescription drug program and enhanced private sector negotiation tools in Medicare; and
- Our perspectives on Medicare drug pricing policies that have been recommended by the Medicare Payment Advisory Commission (MedPAC) and by the President’s budget for fiscal year 2020.